Pfizer Financial Statements From 2010 to 2025

PFE Stock   12.14  0.13  1.08%   
Pfizer financial statements provide useful quarterly and yearly information to potential Pfizer Inc CDR investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pfizer financial statements helps investors assess Pfizer's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pfizer's valuation are summarized below:
Gross Profit
47.2 B
Profit Margin
0.1262
Market Capitalization
212.7 B
Enterprise Value Revenue
3.0005
Revenue
63.6 B
We have found seventy-nine available trending fundamental ratios for Pfizer Inc CDR, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Pfizer's recent fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road.

Pfizer Total Revenue

71.04 Billion

Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Interest Income of 485.3 M, Discontinued Operations of 5.1 M or Interest Expense of 1.9 B, as well as many indicators such as . Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
  
This module can also supplement various Pfizer Technical models . Check out the analysis of Pfizer Correlation against competitors.

Pfizer Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets204.2 B213.4 B173.7 B
Slightly volatile
Other Current Liabilities19.9 B19.7 B15.2 B
Slightly volatile
Total Current Liabilities42.5 B43 B35.5 B
Slightly volatile
Total Stockholder Equity84.8 B88.2 B70.7 B
Slightly volatile
Other Liabilities21.3 B21 B27.7 B
Slightly volatile
Net Debt51.5 B62.6 B43.8 B
Slightly volatile
Retained Earnings116.6 B116.7 B98.4 B
Slightly volatile
Accounts Payable5.9 B5.6 B5.1 B
Slightly volatile
Cash1.6 BB1.3 B
Slightly volatile
Non Current Assets Total153.6 B163 B125.4 B
Slightly volatile
Non Currrent Assets Other8.6 B9.8 B5.4 B
Slightly volatile
Other Assets11.7 B19.4 B8.5 B
Slightly volatile
Long Term Debt45.2 B56.7 B37 B
Slightly volatile
Net Receivables11.7 B11.5 B11.1 B
Pretty Stable
Good Will62.6 B68.5 B55.5 B
Slightly volatile
Common Stock Shares Outstanding6.2 B5.7 B5.7 B
Pretty Stable
Short Term Investments18.4 B19.4 B17.3 B
Very volatile
Non Current Liabilities Total76.6 B81.9 B67.1 B
Slightly volatile
Inventory9.7 B10.9 B8.2 B
Slightly volatile
Other Current Assets4.6 B4.3 B8.9 B
Slightly volatile
Total Liabilities119.1 B124.9 B102.6 B
Slightly volatile
Net Invested Capital138 B151.9 B115.8 B
Slightly volatile
Long Term Investments2.1 B2.2 B7.6 B
Slightly volatile
Short and Long Term Debt5.7 B6.9 B7.9 B
Slightly volatile
Total Current Assets50.7 B50.4 B48.3 B
Pretty Stable
Capital Stock382.6 M480 M476.2 M
Slightly volatile
Non Current Liabilities Other11.4 B14.2 B8.2 B
Slightly volatile
Intangible Assets45.2 B55.4 B38.4 B
Slightly volatile
Common Stock517.9 M547.4 M477 M
Slightly volatile
Property Plant Equipment17.5 B22.2 B15.4 B
Slightly volatile
Property Plant And Equipment Net17.7 B18.4 B15 B
Slightly volatile
Property Plant And Equipment Gross35 B34.9 B31.4 B
Slightly volatile

Pfizer Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income485.3 M545 M389.8 M
Slightly volatile
Interest Expense1.9 B3.1 B1.5 B
Slightly volatile
Selling General Administrative15.1 B14.7 B14.2 B
Pretty Stable
Total Revenue71 B63.6 B59.5 B
Slightly volatile
Gross Profit49.3 B45.8 B43.9 B
Pretty Stable
Other Operating Expenses801.6 M901.8 M983.2 M
Slightly volatile
Operating Income18 B14.9 B15.8 B
Pretty Stable
Net Income From Continuing Ops11.3 B8.1 B12.5 B
Pretty Stable
EBIT47.1 B44.8 B17.6 B
Slightly volatile
Research Development11.4 B10.8 B9.3 B
Slightly volatile
EBITDA28.4 B45.5 B24.9 B
Slightly volatile
Cost Of Revenue21.7 B17.9 B15.6 B
Slightly volatile
Total Operating Expenses53 B48.7 B43.7 B
Slightly volatile
Reconciled Depreciation6.2 BBB
Slightly volatile
Income Before Tax12 BB13.3 B
Pretty Stable
Net Income Applicable To Common Shares19.7 B36.1 B16.6 B
Slightly volatile
Net Income11.5 BB12.6 B
Pretty Stable

Pfizer Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow12.5 B9.8 B14.4 B
Very volatile
Begin Period Cash Flow1.9 B2.9 B1.6 B
Slightly volatile
Depreciation6.3 BB5.9 B
Pretty Stable
Dividends Paid9.6 B9.5 B8.4 B
Slightly volatile
Capital ExpendituresB2.9 B2.4 B
Slightly volatile
Total Cash From Operating Activities20.3 B12.7 B17.3 B
Pretty Stable
Net Income11.5 BB12.6 B
Pretty Stable
End Period Cash Flow1.8 B1.1 B1.4 B
Slightly volatile
Stock Based Compensation948.4 M877 M786.5 M
Slightly volatile

Pfizer Fundamental Market Drivers

Forward Price Earnings8.285

About Pfizer Financial Statements

Pfizer investors utilize fundamental indicators, such as revenue or net income, to predict how Pfizer Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue63.6 B71 B
Cost Of Revenue17.9 B21.7 B

Pair Trading with Pfizer

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.

Moving against Pfizer Stock

  0.56SSV Southern Silver Expl Earnings Call This WeekPairCorr
  0.55ASCU Arizona Sonoran CopperPairCorr
  0.5SAM Starcore InternationalPairCorr
  0.5KNT K92 MiningPairCorr
  0.48ARG Amerigo ResourcesPairCorr
The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc CDR to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Pfizer Stock

Pfizer financial ratios help investors to determine whether Pfizer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pfizer with respect to the benefits of owning Pfizer security.